Article

Schwind eye-tech-solutions premieres new excimer laser

Kleinosheim, Germany-Schwind eye-tech-solutions premiered its new excimer laser (Amaris) at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Kleinosheim, Germany-Schwind eye-tech-solutions premiered its new excimer laser (Amaris) at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Among its features, the laser offers a pulse frequency of 500 Hz, two automatically adapted fluence levels for ablation control, and what the company says is the fastest eye tracker on the market-with a response time of less than 3 milliseconds-compensating every movement of the eye up to the fifth dimension. In addition, with online pachymetry, the laser continuously measures corneal thickness during the treatment, allowing the surgeon to decide at any time how best to proceed with a refractive correction.

One-month results of the first international multicenter LASIK study with the laser are encouraging in regard to visual acuity (VA), predictability, and variance, according to the company. The study involved 389 myopic eyes in patients aged 18 to 60 years. Some of the patients also had astigmatism.

The preoperative spherical equivalent (SE) ranged from –0.50 to –8.25 D, and astigmatism was treated up to –5.00 D. Postoperatively, an average SE of –0.16 D with a standard deviation of 0.25 D was observed. In 74% of all treated eyes, the planned refractive result was achieved within a minimum deviation of ±0.25 D after 1 month. Ninety-three percent of eyes were in the range of ±0.50 D, and 100% of eyes were within ±1.00 D. High postoperative stability was observed after 1 week.

Also after 1 month, postoperative uncorrected VA of 20/20 or better was achieved in more than 92% of treated patients. No single patient eye had a VA of less than 20/32. In 99%, a UCVA of 20/25 or better was achieved, and VA of 20/16 or better was achieved in more than 32% of study participants.

No trend toward overcorrection or undercorrection was detected after 1 month. All results were obtained without the use of individual nomograms.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.